Table 9.
Adverse Event | Placebo (n = 36) |
OnabotA 240 U (n = 36) | OnabotA 360 U (n = 36) |
---|---|---|---|
Overall | 11 (30.6%) | 8 (22.9%) | 16 (43.2%) |
Nasopharyngitis | 2 (5.6%) | 3 (8.6%) | 6 (16.2%) |
Bronchitis | 0 (0.0%) | 1 (2.9%) | 2 (5.4%) |
Upper respiratory tract infection | 2 (5.6%) | 0 (0.0%) | 2 (5.4%) |
Oropharyngeal pain | 0 (0.0%) | 2 (5.7%) | 1 (2.7%) |